IRCT20220424054645N1 IRCT 2022-05-18 Bandare-abbas University of Medical Sciences Effect of Livergol in treatment of thalassemia major and intermedia Evaluation the efficacy of Livergol(Sylimarin extract) on liver function of thalassemia major and intermedia patients: A triple-blinded, randomized, placebo-controlled trial 2022-06-22 anticipated 80 Complete https://irct.ir/trial/63304 interventional Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Simple,Block, Blinding description: All participants are aware of participating in this study and enter the study with their consent.The participant , care provider and investigators do not know which box contains placebo tablets and which contains Livergol tablets. 3 Thalassemia. Intervention 1: Intervention group: In cases under 12 years of age take one tablet(70 mg)and over 12 years of age take two tablets(140 mg) of Livergol oral pills ,product of Goldaru pharmaceutical company, three times per day, for 3 months. Intervention 2: Control group: The same placebo ,product of pharmaceutical company,take three times per day, for 3 months. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is there is no more data